Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 21, 2022 |
Director, CEO & President
|
Director, CEO & President | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 405,040 | -- | 1,213,340 |
| Jun 21, 2022 |
Director, CEO & President
|
Director, CEO & President | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,078,500 | -- | 1,078,500 |
| Jun 21, 2022 |
Director, CEO & President
|
Director, CEO & President | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,488,940 | -- | 1,488,940 |
| Jun 21, 2022 |
Former Director
|
Former Director | Form 4 | Open market or private sale of non-derivative or derivative security | 4,283 | $0.79 | 82,063 |
| Mar 25, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 4,759 | -- | 4,759 |
| Mar 25, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 22,601 | -- | 22,601 |
| Feb 24, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 15,031 | $0.64 | 275,916 |
| Feb 24, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Other acquisition or disposition | -- | -- | 6,250 |
| Feb 23, 2022 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 13,513 | $0.70 | 290,947 |
| Feb 14, 2022 |
Director, CEO & President
|
Director, CEO & President | Form 5 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 239,500 | -- | 1,213,340 |
| Feb 14, 2022 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 10,000 | $0.69 | 170,244 |
| Jun 23, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 5,000 | $4.00 | 340,046 |
| Jun 23, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Other acquisition or disposition | -- | -- | 7,226 |
| Jun 22, 2021 |
Chief Medical Officer
|
Chief Medical Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 5,821 | $4.09 | 345,046 |
| Jun 22, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 4,500 | $4.16 | 303,699 |
| Jun 22, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Other acquisition or disposition | -- | -- | 6,250 |
| Jun 21, 2021 |
Chief Legal Officer
|
Chief Legal Officer | Form 4 | Open market or private sale of non-derivative or derivative security | 3,735 | $4.27 | 308,199 |
| Jun 18, 2021 |
Director
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 9,000 | $4.24 | 46,943 |
| Jun 18, 2021 |
Director
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 12,000 | $4.24 | 34,777 |
| Jun 18, 2021 |
Director
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 9,000 | $4.24 | 86,346 |
| Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 55,943 |
| Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
| Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 29,277 |
| Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 67,804 | -- | 67,804 |
| Jun 17, 2021 |
Director
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 14,277 | -- | 46,777 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.